CoChat
Sign Up
Cited by 192Ovarian cancer diagnosis and treatmentGene expression and cancer classificationBreast Cancer Treatment Studies

The DOI matches its Crossref record.

Gene Expression Profiles Associated with Response to Chemotherapy in Epithelial Ovarian Cancers

Jazaeri, Amir A., Awtrey, Christopher S., Chandramouli, Gadisetti V.R., Chuang, Yao Eric, Khan, Javed, Sotiriou, Christos, Aprelikova, Olga, Yee, Cindy J., Zorn, Kristin K., Birrer, Michael J., Barrett, J. Carl, Boyd, Jeff·2005·Clinical Cancer Research
DOI 10.1158/1078-0432.ccr-04-2682

Published version of a preprint

Open this paper in CoChat — free account

Abstract

Purpose: The goal of this study was to determine whether distinct gene expression profiles are associated with intrinsic and/or acquired chemoresistance in epithelial ovarian carcinoma. Experimental Design: Gene expression profiles were generated from 21 primary chemosensitive tumors and 24 primary chemoresistant tumors using cDNA-based microarrays. Gene expression profiles of both groups of primary tumors were then compared with those of 15 ovarian carcinomas obtained following platinum-based chemotherapy (“postchemotherapy” tumors). A theme discovery tool was used to identify functional categories of genes involved in drug resistance. Results: Comparison of primary chemosensitive and chemoresistant tumors revealed differential expression of 85 genes (P < 0.001). Comparison of gene expression profiles of primary chemosensitive tumors and postchemotherapy tumors revealed more robust differences with 760 genes differentiating the two groups (P < 0.001). In contrast, only 230 genes were differentially expressed between primary chemoresistant and postchemotherapy groups (P < 0.001). Common to both gene lists were 178 genes representing transcripts differentially expressed between postchemotherapy tumors and all primary tumors irrespective of intrinsic chemosensitivity. The gene expression profile of postchemotherapy tumors compared with that of primary tumors revealed statistically significant overrepresentation of genes encoding extracellular matrix–related proteins. Conclusions: These data show that gene expression profiling can discriminate primary chemoresistant from primary chemosensitive ovarian cancers. Gene expression profiles were also identified that correlate with states of intrinsic and acquired chemoresistance and that represent targets for future investigation and potential therapeutic interventions.

Overview

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-04-2682

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

No references could be resolved yet.

Research works printed but not linked: 47

  1. Chi DS, Sabbatini P. Advanced ovarian cancer. Curr Treat Options Oncol 2000;1:139–46. · DOI
  2. Salom E, Almeida Z, Mirhashemi R. Management of recurrent ovarian cancer: evidence-based decisions. Curr Opin Oncol 2002;14:519–27. · DOI
  3. McGuire WP, Markman M. Primary ovarian cancer chemotherapy: current standards of care. Br J Cancer 2003;89:S3–8. · DOI
  4. Markman M, Hoskins W. Responses to salvage chemotherapy in ovarian cancer: a critical need for precise definitions of the treated population [editorial]. J Clin Oncol 1992;10:513–4. · DOI
  5. Alberts DS. Treatment of refractory and recurrent ovarian cancer. Semin Oncol 1999;26:8–14.
  6. Spriggs D. Optimal sequencing in the treatment of recurrent ovarian cancer. Gynecol Oncol 2003;90:S39–44. · DOI
  7. Johnson SW, Ozols RF, Hamilton TC. Mechanisms of drug resistance in ovarian cancer. Cancer 1993;71:644–9. · DOI
  8. Aebi S, Kurdihaidar B, Gordon R, et al. Loss of DNA mismatch repair in acquired resistance to cisplatin. Cancer Res 1996;56:3087–90.
  9. Coukos G, Rubin SC. Chemotherapy resistance in ovarian cancer: new molecular perspectives. Obstet Gynecol 1998;91:783–92. · DOI
  10. Vasey PA. Resistance to chemotherapy in advanced ovarian cancer: mechanisms and current strategies. Br J Cancer 2003;89:S23–8. · DOI
  11. Agarwal R, Kaye SB. Ovarian cancer: strategies for overcoming resistance to chemotherapy. Nat Rev Cancer 2003;3:502–16. · DOI
  12. Skipper HE. Kinetics of mammary tumor cell growth and implications for therapy. Cancer 1971;28:1479–99. · DOI
  13. Norton L, Simon R, Brereton HD, Bogden AE. Predicting the course of Gompertzian growth. Nature 1976;264:542–5. · DOI
  14. Van Gelder RN, von Zastrow ME, Yool A, Dement WC, Barchas JD, Eberwine JH. Amplified RNA synthesized from limited quantities of heterogeneous cDNA. Proc Natl Acad Sci U S A 1990;87:1663–7. · DOI
  15. Hosack DA, Dennis G, Sherman BT, Lane HC, Lempicki RA. Identifying biological themes within lists of genes with EASE. Genome Biol 2003;4:R70. · DOI
  16. Losch A, Schindl M, Kohlberger P, et al. Cathepsin D in ovarian cancer: prognostic value and correlation with p53 expression and microvessel density. Gynecol Oncol 2004;92:545–52. · DOI
  17. Ioachim E, Tsanou E, Briasoulis E, et al. Clinicopathological study of the expression of hsp27, pS2, cathepsin D and metallothionein in primary invasive breast cancer. Breast 2003;12:111–9. · DOI
  18. Glondu M, Liaudet-Coopman E, Derocq D, Platet N, Rochefort H, Garcia M. Down-regulation of cathepsin-D expression by antisense gene transfer inhibits tumor growth and experimental lung metastasis of human breast cancer cells. Oncogene 2002;21:5127–34. · DOI
  19. Ioachim E, Charchanti A, Stavropoulos N, Athanassiou E, Bafa M, Agnantis NJ. Expression of cathepsin D in urothelial carcinoma of the urinary bladder: an immunohistochemical study including correlations with extracellular matrix components, CD44, p53, Rb, c-erbB-2 and the proliferation indices. Anticancer Res 2002;22:3383–8.
  20. Mok SC, Wong KK, Chan RK, et al. Molecular cloning of differentially expressed genes in human epithelial ovarian cancer. Gynecol Oncol 1994;52:247–52. · DOI · Paper page
  21. Wiechen K, Diatchenko L, Agoulnik A, et al. Caveolin-1 is down-regulated in human ovarian carcinoma and acts as a candidate tumor suppressor gene. Am J Pathol 2001;159:1635–43. · DOI
  22. Manzano RG, Montuenga LM, Dayton M, et al. CL100 expression is down-regulated in advanced epithelial ovarian cancer and its re-expression decreases its malignant potential. Oncogene 2002;21:4435–7. · DOI
  23. van der Zee AG, Hollema H, de Jong S, et al. P-glycoprotein expression and DNA topoisomerase I and II activity in benign tumors of the ovary and in malignant tumors of the ovary, before and after platinum/cyclophosphamide chemotherapy. Cancer Res 1991;51:5915–20.
  24. Jazaeri AA, Yee CJ, Sotiriou C, Brantley KR, Boyd J, Liu ET. Gene expression profiles of BRCA1-linked, BRCA2-linked, and sporadic ovarian cancers. J Natl Cancer Inst 2002;94:990–1000. · DOI
  25. Tiniakos DG, Yu H, Liapis H. Osteopontin expression in ovarian carcinomas and tumors of low malignant potential (LMP). Hum Pathol 1998;29:1250–4. · DOI
  26. Kim JH, Skates SJ, Uede T, et al. Osteopontin as a potential diagnostic biomarker for ovarian cancer. J Am Med Assoc 2002;287:1671–9. · DOI
  27. Zhang P, Liegeois NJ, Wong C, et al. Altered cell differentiation and proliferation in mice lacking p57KIP2 indicates a role in Beckwith-Wiedemann syndrome. Nature 1997;387:151–8. · DOI
  28. Luque A, Carpizo DR, Iruela-Arispe ML. ADAMTS1/METH1 inhibits endothelial cell proliferation by direct binding and sequestration of VEGF165. J Biol Chem 2003;278:23656–65. · DOI
  29. Babic AM, Kireeva ML, Kolesnikova TV, Lau LF. CYR61, a product of a growth factor-inducible immediate early gene, promotes angiogenesis and tumor growth. Proc Natl Acad Sci U S A 1998;95:6355–60. · DOI · Paper page
  30. Wittig R, Nessling M, Will RD, et al. Candidate genes for cross-resistance against DNA-damaging drugs. Cancer Res 2002;62:6698–705.
  31. Goldie JH, Coldman AJ. A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate. Cancer Treat Rep 1979;63:1727–33.
  32. Ferrandina G, Scambia G, Fagotti A, et al. Immunoradiometric and immunohistochemical analysis of cathepsin D in ovarian cancer: lack of association with clinical outcome. Br J Cancer 1998;78:1645–52. · DOI
  33. Scambia G, Panici PB, Ferrandina G, et al. Clinical significance of cathepsin D in primary ovarian cancer. Eur J Cancer 1994;30A:935–40. · DOI
  34. Baekelandt M, Holm R, Trope CG, Nesland JM, Kristensen GB. The significance of metastasis-related factors cathepsin-D and nm23 in advanced ovarian cancer. Ann Oncol 1999;10:1335–41. · DOI
  35. Wu GS, Saftig P, Peters C, El-Deiry WS. Potential role for cathepsin D in p53-dependent tumor suppression and chemosensitivity. Oncogene 1998;16:2177–83. · DOI
  36. Brustmann H. Apoptotic bodies as a morphological feature in serous ovarian carcinoma: correlation with nuclear grade, Ki-67 and mitotic indices. Pathol Res Pract 2002;198:85–90. · DOI
  37. Sherman-Baust CA, Weeraratna AT, Rangel LB, et al. Remodeling of the extracellular matrix through overexpression of collagen VI contributes to cisplatin resistance in ovarian cancer cells. Cancer Cell 2003;3:377–86. · DOI
  38. Bradshaw AD, Sage EH. SPARC, a matricellular protein that functions in cellular differentiation and tissue response to injury. J Clin Invest 2001;107:1047–54. · DOI
  39. Korn EL, McShane LM, Troendle JF, Rosenwald A, Simon R. Identifying pre-post chemotherapy differences in gene expression in breast tumours: a statistical method appropriate for this aim. Br J Cancer 2002;83:1093–6. · DOI
  40. Mok SC, Chan WY, Wong KK, Muto MG, Berkowitz RS. SPARC, an extracellular matrix protein with tumor-suppressing activity in human ovarian epithelial cells. Oncogene 1996;12:1895–901.
  41. Yiu GK, Chan WY, Ng SW, et al. SPARC (secreted protein acidic and rich in cysteine) induces apoptosis in ovarian cancer cells. Am J Pathol 2001;159:609–22. · DOI
  42. Dhanesuan N, Sharp JA, Blick T, Price JT, Thompson EW. Doxycycline-inducible expression of SPARC/osteonectin/BM40 in MDA-MB-231 human breast cancer cells results in growth inhibition. Breast Cancer Res Treat 2002;75:73–85. · DOI
  43. Gilles C, Bassuk JA, Pulyaeva H, Sage EH, Foidart JM, Thompson EW. SPARC/osteonectin induces matrix metalloproteinase 2 activation in human breast cancer cell lines. Cancer Res 1998;58:5529–36.
  44. Fujita T, Shiba H, Sakata M, Uchida Y, Nakamura S, Kurihara H. SPARC stimulates the synthesis of OPG/OCIF, MMP-2 and DNA in human periodontal ligament cells. J Oral Pathol Med 2002;31:345–52. · DOI
  45. Claeskens A, Ongenae N, Neefs JM, et al. Hevin is down-regulated in many cancers and is a negative regulator of cell growth and proliferation. Br J Cancer 2000;82:1123–30. · DOI
  46. Chen X, Whitney EM, Gao SY, Yang VW. Transcriptional profiling of Kruppel-like factor 4 reveals a function in cell cycle regulation and epithelial differentiation. J Mol Biol 2003;326:665–77. · DOI
  47. McCluggage WG, Lyness RW, Atkinson RJ, et al. Morphological effects of chemotherapy on ovarian carcinoma. J Clin Pathol 2002;55:27–31. · DOI

Cited by

Sorted by citations

Metadata

Authors
Jazaeri, A. A., Awtrey, C. S., Chandramouli, G. V. R., Chuang, Y. E., Khan, J., Sotiriou, C., Aprelikova, O., Yee, C. J., Zorn, K. K., Birrer, M. J., Barrett, J. C., & Boyd, J.
Affiliations
  • 1Laboratory of Biosystems and Cancer and
  • 4Gynecology and Breast Research Laboratory, Department of Surgery, and
  • Center for Cancer Research (US)
  • National Cancer Institute (US)
  • Memorial Sloan Kettering Cancer Center (US)
ORCID
Venue
Clinical Cancer Research
Publisher
American Association for Cancer Research (AACR)
Published
2005-09-01
Volume
11
Issue
17
Pages
6300-6310
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
DOI
10.1158/1078-0432.ccr-04-2682
OpenAlex
W2109449896
Cited by
192
References
0
Citations by year
2025: 1 · 2024: 7 · 2023: 12 · 2022: 4 · 2021: 6 · 2020: 4 · 2019: 4 · 2018: 7 · 2017: 4 · 2016: 10 · 2015: 14 · 2014: 9 · 2013: 12 · 2012: 19
FWCI
14.77
Type
journal article
Language
en
Open access
closed
Locations
  • Clinical Cancer Research (publishedVersion)
  • PubMed (publishedVersion)
  • Dépôt institutionnel de l'Université libre de Bruxelles (Université Libre de Bruxelles) (submittedVersion)
Funders
National Cancer Institute (U01CA088175, U01CA88175)
Topics
  • Health Sciences › Medicine › Oncology › Ovarian cancer diagnosis and treatment
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gene expression and cancer classification
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
Keywords
epithelial ovarian cancer, chemoresistance, gene expression profiling, acquired chemoresistance, platinum-based chemotherapy, extracellular matrix genes, differential gene expression
MeSH terms
Adult, Aged, Aged, 80 and over, Antineoplastic Agents, Female, Humans, Immunoenzyme Techniques, Middle Aged, Neoplasm Proteins, Neoplasm Staging, Ovarian Neoplasms, RNA, Neoplasm, Biomarkers, Tumor, Gene Expression Regulation, Neoplastic, Carcinoma, Endometrioid, Cystadenocarcinoma, Serous, Reverse Transcriptase Polymerase Chain Reaction, Oligonucleotide Array Sequence Analysis, Gene Expression Profiling

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review